Fig. 2: Analysis of tumor transcriptomes indicates patients with durable clinical benfit exhibit greater immune activation compared to patients with limited clinical benefit.

a Through Gene Set Enrichment Analysis (GSEA) of tumor transcriptome data, immune population changes are found to be enriched in durable clinical benefit (DCB) groups, with this enrichment further amplified during treatment (On.TX) compared to limited clinical benefit (LCB) groups. Additionally, MYC-associated and neuronal signatures are more prevalent in LCB groups compared to DCB groups, irrespective of the timepoint (Baseline or On.TX). b Quantification of immune-specific signatures based on GSEA, demonstrates increases in immune-associated transcripts in DCB, as compared to LCB populations, including those associated with T cells, B cells, CD40 signaling, and tertiary lymphoid structures (TLS). Further, this corresponds with (c) enrichment of MCP Counter immune deconvolution signatures in DCB patient populations compared to LCB patient populations at baseline, and further exacerbated by treatment. d This is further exemplified in comparing MCP counter cytotoxicity, T cell, B cell, and myeloid dendritic cell (DC) signatures. *p < 0.05, **p < 0.01, two-sided Mann–Whitney U-Test. Exact p-values can be found in Data Table 1.